top of page

Swiss Nordic Bio 2026: Amphilix believes in using small ligands and small molecule linkers for radiopharmaceuticals - the lead program will target GPL4

15 minutes ago

1 min read

Founder and Chairman Kevin McAllister describes the platform and why he believes theirs is a better approach to radiopharmaceuticals.

https://vimeo.com/1231951921?share=copy&fl=sv&fe=ci

Coverage brought to you by

Recent Posts

Veradermics, a company trying to change hair loss, so far has been one of the best performing IPOs in biotech in many years

Veradermics, a company trying to change hair loss, so far has been one of the best performing IPOs in biotech in many years

Roivant has had a big year of success on multiple fronts - CEO Matt Gline shares an update on a key launch, and two closely watched programs

Roivant has had a big year of success on multiple fronts - CEO Matt Gline shares an update on a key launch, and two closely watched programs

From Basel: TOLREMO Therapeutics is working on cancer resistance - the company is targeting CBP/p300 just stared phase 1 data at World Lung

From Basel: TOLREMO Therapeutics is working on cancer resistance - the company is targeting CBP/p300 just stared phase 1 data at World Lung

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsors

10x_Genomics_logo.svg.png

NYSE_logo_large_no reg_378x197 (1).png

Learn more about our sponsors

Sponsor Spotlight

10x_Genomics_logo.svg.png

10x Genomics delivers powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology to advance human health. Cited in more than 10,000 research papers, our innovative single cell, spatial, and in situ technologies enable discoveries across oncology, immunology, neuroscience, and more.

Our talented, dedicated science professionals have a distinguished record of creating innovative instruments, reagents, and software that analyze biological systems at a resolution that matches the complexity of biology.

bottom of page